A CCR2/5 Inhibitor, PF-04634817, Is Inferior to Monthly Ranibizumab in the Treatment of Diabetic Macular Edema | Zendy

Jeremy D. Gale | Zendy; Brian B. Berger | Zendy; Steven A. Gilbert | Zendy; Serghei Popa | Zendy; Marla B. Sultan | Zendy; Ronald A. Schachar | Zendy; Douglas Girgenti | Zendy; Christelle Perros-Huguet | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

A CCR2/5 Inhibitor, PF-04634817, Is Inferior to Monthly Ranibizumab in the Treatment of Diabetic Macular Edema

Author(s) -

Jeremy D. Gale,

Brian B. Berger,

Steven A. Gilbert,

Serghei Popa,

Marla B. Sultan,

Ronald A. Schachar,

Douglas Girgenti,

Christelle Perros-Huguet

Publication year - 2018

Publication title -

investigative ophthalmology and visual science

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.935

H-Index - 218

eISSN - 1552-5783

pISSN - 0146-0404

DOI - 10.1167/iovs.17-22731

Subject(s) - ranibizumab , diabetic macular edema , medicine , ophthalmology , diabetes mellitus , diabetic retinopathy , endocrinology , chemotherapy , bevacizumab

Ligands for the proinflammatory C-C chemokine receptor types 2 and 5 (CCR2 and CCR5) are elevated in the eyes of patients with diabetic macular edema (DME). We evaluated the efficacy and safety of PF-04634817, an oral CCR2/5 dual antagonist, versus intravitreal ranibizumab, in adult subjects with DME.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research